Skip to content
Clinical Trials – home
Therapeutic area

Congenital, familial and genetic disorders – page 61

  • 803 clinical trials
  • 311 recruiting
  • 375 conditions
  • 27 countries

Conditions in this area

375 conditions with trials, the busiest first

Clinical trials in Congenital, familial and genetic disorders

803 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

803 clinical trials

Study of MK-0616 for Adults with Familial Hypercholesterolemia

Investigational
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Enlicitide Chloride
  • Sponsor:Merck Sharp & Dohme LLC

Ichthyosis+1

Not recruiting

Study on the Effects of Deucravacitinib for Adults with Inflammatory Skin Conditions (Epidermolysis Bullosa Simplex and Congenital Ichthyoses)

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Deucravacitinib
  • Sponsor:Centre Hospitalier Universitaire De Nice

Study on the Safety and Effectiveness of CRN04894 for Patients with Congenital Adrenal Hyperplasia

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Abiraterone Acetate
  • Sponsor:Crinetics Pharmaceuticals Inc.

Cystic fibrosis

Not recruiting

Study on VX-522 and Ivacaftor for Adults with Cystic Fibrosis Unresponsive to CFTR Modulator Therapy

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years
  • Substances:Ivacaftor
  • Sponsor:Vertex Pharmaceuticals Inc.

Study on the Effects of Romosozumab and Bisphosphonates in Children and Adolescents with Osteogenesis Imperfecta

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:0–17 years
  • Substances:Calcium
  • Sponsor:Amgen Inc.

Long-term Safety Study of Mavacamten for Adults with Hypertrophic Cardiomyopathy from Previous Trials

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Mavacamten
  • Sponsor:Myokardia Inc.

Study on the Safety and Effects of STAR-0215 for Adults with Hereditary Angioedema

InvestigationalNo placebo
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:STAR-0215
  • Sponsor:Astria Therapeutics Inc.

Hereditary angioedema

Not recruiting

Study on the Safety and Effects of Garadacimab for Preventing Hereditary Angioedema in Children Aged 2 to 11

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:Garadacimab
  • Sponsor:CSL Behring LLC

Netherton's syndrome

Not recruiting

Study on the Safety and Effectiveness of SXR1096 Cream for Patients with Netherton Syndrome

InvestigationalNo placebo
Countries:AustriaAustria
  • Participants:18–64 years
  • Substances:SXR1096
  • Sponsor:Sixera Pharma AB

Cerebral palsy+5

Not recruiting

Study on Valbenazine for Treating Dyskinesia in Children and Adults with Cerebral Palsy

Investigational
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Valbenazine Ditosylate
  • Sponsor:Neurocrine Biosciences Inc.

Study on the Safety and Efficacy of Cipaglucosidase Alfa and Miglustat for Children with Late-onset Pompe Disease

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:Cipaglucosidase Alfa
  • Sponsor:Amicus Therapeutics Inc.

Muscular dystrophy

Not recruiting

Gene Therapy Study for Patients with Limb-Girdle Muscular Dystrophy Using GNT0006

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Abiraterone Acetate
  • Sponsor:Atamyo Therapeutics

Substances studied in this area

The therapies tested most often in Congenital, familial and genetic disorders trials.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.